এস্তোনিয়া - এস্তোনীয় - Ravimiamet

teva b.v. - tsinakaltseet - õhukese polümeerikattega tablett - 60mg 14tk; 60mg 30tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

pharmaceutical works polpharma s.a. - kvetiapiin - õhukese polümeerikattega tablett - 100mg 90tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

pharmaceutical works polpharma s.a. - kvinapriil - õhukese polümeerikattega tablett - 40mg 30tk

এস্তোনিয়া - এস্তোনীয় - Ravimiamet

pharmaceutical works polpharma s.a. - kvinapriil - õhukese polümeerikattega tablett - 10mg 30tk

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

albireo - odevixibat - cholestasis, intrahepatic - vere ja maksa ravi - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 ja 5.

এস্তোনিয়া - এস্তোনীয় - Ecolab

ecolab deutschland gmbh -

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

h. lundbeck a/s - eptinezumab - migreenihäired - valuvaigistid - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

gilead sciences ireland uc - bictegravir, emtricitabine, tenofovir alafenamide, dietüülfumaraat - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (vt punkt 5).

ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

merck sharp & dohme b.v. - doravirine, lamivudine, tenofovir disoproxil dietüülfumaraat - hiv-nakkused - viirusevastased ravimid hiv-infektsioonide raviks, kombinatsioonid - delstrigo on näidustatud ravi täiskasvanud nakatunud hiv-1, ilma et varem või esitab tõendid takistuse nnrti klassi, lamivudine, või tenofovir. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.